Literature DB >> 32576122

Informed Consent: A Policy Prescription for Communicating Benefit and Risk in State Medical Marijuana Programs.

Erik Messamore1, Sara E Dugan1.   

Abstract

In creating medical marijuana laws, state governments signal to the public that marijuana can safely and effectively treat a wide range of diseases. In many cases, these state approvals overestimate the benefits of marijuana and understate the risks. After a comprehensive review of the medical literature, the National Academies of Sciences, Engineering, and Medicine identified six medical benefits from marijuana that were supported with at least a moderate level of medical evidence and 14 potential health hazards. In contrast, the average state medical marijuana program lists 18 medical benefits, and 24 state medical marijuana program websites say nothing about possible risks. Medication approval processes through the federal government traditionally require independent analysis of data from well-designed clinical trials that measure the effectiveness and capture the risks of adverse effects from specific doses of the medicine. These considerations are generally missing from state approvals of medical marijuana. The power to declare something to be a legitimate medicine comes with the responsibility to provide information that people need to use the medicine wisely. The authors recommend that states that declare marijuana to be a medicine should inform the public about the quality of medical evidence behind each approved use and publicize all scientifically credible risks.

Entities:  

Keywords:  Cannabis; Drug-Related Side Effects and Adverse Reactions; Information Dissemination; Marijuana Use; Medical Marijuana; Policy Making

Mesh:

Substances:

Year:  2020        PMID: 32576122     DOI: 10.1176/appi.ps.202000140

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  1 in total

1.  From Underground to Mainstream: Establishing a Medical Lexicon for Psychedelic Therapy.

Authors:  Andrew Beswerchij; Dominic Sisti
Journal:  Front Psychiatry       Date:  2022-06-17       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.